Biased complement inhibitory hybrid protein
By developing hybrid proteins containing functional units of different complement factor, the problem of decreased immune function and bias of existing complement inhibitors when regulating the complement system is solved, efficient inhibition of alternative pathways and partial retention of classical pathways are achieved, providing More accurate and effective treatment options.
Patent Information
- Application Number
- PCT/CN2023/094269
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-15
- Publication Date
- 2024-11-21
AI Technical Summary
Existing complement inhibitors will lead to a decrease in immune function and increase the risk of infection when completely inhibiting complement activity. Different complement regulatory proteins have biased inhibitory activity, making it difficult to accurately regulate the complement system, especially between classical and alternative pathways. Balance problem.
Develop hybrid proteins containing functional units of different complement factor, such as hybrid proteins of CFH and DAF, by combining CCP1-2 of CFH and CCP4 of DAF, or CCP15 of CR1 and CCP3-4 of DAF, to form biased complement inhibition Functional proteins attenuate the inhibitory activity of classical pathways and enhance the inhibitory activity of alternative pathways, thereby retaining or partially retaining the immune function of classical pathways when treating diseases with dysregulated alternative pathways.
It realizes that when treating diseases with dysfunction of alternative pathways, significantly enhances the inhibitory activity of alternative pathways, while attenuating the inhibition of classical pathways, provides more accurate therapeutic options, and shows better efficacy and tissue penetration in drug applications. Permeability.
Smart Images

Figure PCTCN2023094269-FTAPPB-I100001 
Figure PCTCN2023094269-FTAPPB-I100002 
Figure PCTCN2023094269-FTAPPB-I100003
Abstract
Description
Biased complement inhibition hybrid protein Technical Field
[0001] The present invention belongs to the fields of medical immunology and recombinant proteins, and specifically relates to a hybrid protein comprising functional units of different complement factors, its encoding nucleic acid, and a method and use thereof for treating diseases or disorders related to the complement system. Background Art
[0002] The complement system is part of the innate immune system, composed of over 30 soluble protein molecules. Its components include intrinsic complement components, multiple regulatory factors, and complement receptors. The complement system is known to act directly on pathogens; promote pathogen-specific adaptive immune responses; and participate in cell differentiation and polarization, tissue regeneration, lipid metabolism, clearance of immune complexes, and apoptosis.
[0003] Depending on the initiating factors of activation, complement can be divided into three activation pathways: the classical pathway (CP), the alternative pathway (AP), and the lectin pathway (LP).
[0004] Lack of regulation or inappropriate activation of complement can lead to damage to host tissues, so the complement system is tightly regulated by a family of proteins. Among them, the regulatory complement activation (RCA) family of proteins is primarily responsible for complement regulation. RCA proteins include membrane proteins such as decay-accelerating factor (DAF or CD55), membrane cofactor protein (MCP or CD46), complement receptor 1 (CR1 or CD35), complement receptor 2 (CR2 or CD21), CR1L, CRIg, Crry, CD59, and fluid-phase proteins such as factor H (FH or CFH) and C4b-binding protein (C4BP). Structurally, RCA proteins are composed of complement control protein repeat (CCP) modules, of which 2-4 consecutive modules contribute to regulatory functions known as decay-accelerating activity (DAA) and cofactor activity (CFA). RCA proteins exert their effects by targeting the C3 / C5 convertase, a central enzyme in the complement pathway. To inactivate these enzymes, RCA proteins bind to these convertases or their non-catalytic subunits and inactivate them through different mechanisms. When exerting DAA activity, RCA protein binds to the convertase and irreversibly dissociates its subunits, inactivating it; while when exerting CFA activity, RCA protein binds to the non-catalytic subunits of the convertase (C3b / C4b) and recruits serine protease factor I (FI) to cleave and inactivate it, thereby stopping its ability to form C3 convertase.
[0005] CFH inhibits C3b expansion. It is a cofactor for the factor I-catalyzed cleavage of C3b into iC3b and is an opsonin and ligand for complement receptors 2 and 3. It accelerates the irreversible dissociation of the alternative pathway C3 convertase C3bBb and may also compete with factor B for binding to C3b during the formation of the proconvertase. FH is soluble and is important for protecting surfaces (including the extracellular matrix ECM). Factor H binds to adrenomedullin (a peptide hormone) and may prevent its degradation. FH plays a role in managing cellular aging, stress, or damage through interactions with C-reactive protein, pentraxin, DNA, histones, annexin II, malondialdehyde-acetaldehyde adducts of proteins, and oxidized lipids. FHL1 also has factor I cofactor activity and C3bBb decay-accelerating activity (The Complement Facts Book. Edited by: Scott Barnum and Theresa Schein, Copyright). 2018 Elsevier Ltd. All rights reserved. https: / / doi.org / 10.1016 / C2015-0-06595-9, Chapter 30).
[0006] CR1 is a type I transmembrane N-linked glycoprotein primarily expressed on blood cells and involved in innate immunity. The gene encoding CR1 is a member of the RCA cluster located on chromosome 1. The extracellular domain of CR1 contains binding sites for all primary complement fragments, C3b, C4d, and C1q, as well as for mannan-binding lectin and Epstein-Barr virus. On circulating nucleated cells, CR1 participates in the phagocytosis of complement opsonized particles and immune complexes. Expression levels in circulating red blood cells (RBCs) are genetically determined and vary between 90, 500, or 1200 CR1 copies per cell. In humans, there are no known congenital CR1 deficiencies. Acquired low expression levels of CR1 on circulating RBCs are seen during pregnancy and in a wide range of chronic and acute inflammatory diseases. Mice do not express CR1, but instead express an alternatively spliced variant of CR2. (The Complement Facts Book. Edited by: Scott Barnum and Theresa Schein, Copyright) 2018 Elsevier Ltd. All rights reserved. https: / / doi.org / 10.1016 / C2015-0-06595-9, Chapter 28)
[0007] DAF inhibits the cleavage of C3 and C5 by preventing the formation of classical and alternative C3 and C5 convertases and accelerating their decay, essentially protecting host cells from autologous complement attack. When purified DAF is added to cells, it is able to integrate into the cell membrane and show functional activity. DAF has also been found to regulate T cell tolerance, thereby negatively regulating animal models of various autoimmune diseases (The Complement Facts Book. Edited by: Scott Barnum and Theresa Schein, Copyright). 2018 Elsevier Ltd. All rights reserved. https: / / doi.org / 10.1016 / C2015-0-06595-9, Chapter 25).
[0008] Utilizing natural complement regulatory proteins to inhibit complement activity has therapeutic potential, but complete or comprehensive complement inhibition can reduce immunity and increase the risk of infection. For example, meningococcal vaccination is required before treatment with the C5 antibody drug SOLIRIS, and treatment with the C3 inhibitor EMPAVELI also increases the risk of infection with meningococci, Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type B. Because different RCAs or RCA domains have biased complement inhibitory activity, for example, FH and FHL1 are more inclined to inhibit AP activity, DAF has inhibitory activity against both AP and CP, and different fragment regions of CR1 also have different activities, it is possible to obtain potent and precise complement inhibitory proteins with biased activity by hybridizing functional units of different RCAs, thereby providing better options for the treatment of complement-related diseases.
[0009] SUMMARY OF THE INVENTION
[0010] The present invention provides hybrid proteins comprising functional units of different complement factors. These hybrid proteins exhibit biased complement inhibition, with reduced classical pathway (CP) inhibitory activity and enhanced alternative pathway (AP) inhibitory activity. Thus, they can treat diseases caused by AP activity (such as paronychia nodosum), while preserving or partially preserving the immune function of the CP pathway. Consequently, the present invention also provides methods for the precise treatment of complement AP activity disorders.
[0011] Specifically, the present invention provides a hybrid protein of CFH and DAF, wherein CCP1-2 / SCR1-2 of CFH is hybridized with CCP of DAF (eg CCP4 / SCR4 of DAF) to form a hybrid protein.
[0012] The present invention also provides a hybrid protein of CR1 and DAF, wherein CCP15 / SCR15 of CR1 is hybridized with CCP of DAF (eg CCP3-4 / SCR3-4 of DAF) to form the hybrid protein.
[0013] In some embodiments, the hybrid protein of the present invention can effectively inhibit hemolysis of the human complement pathway. In some specific embodiments, the hybrid protein of the present invention can effectively inhibit hemolysis of the human complement alternative pathway.
[0014] In some embodiments, the hybrid proteins of the present invention have a relatively low molecular weight, allowing for higher molar concentrations at the same mass concentration compared to other commonly used complement regulatory proteins with larger molecular weights. This has the potential for improved efficacy or longer dosing intervals, such as in ophthalmology and neurology. In some embodiments, the hybrid proteins of the present invention exhibit enhanced tissue penetration, such as through tumor tissue and the blood-brain barrier.
[0015] In some embodiments, the present invention relates to the following specific items:
[0016] 1. A hybrid protein comprising
[0017] (i) CCP1-2 of human complement factor H (CFH),
[0018] (ii) CCP4 of human decay-accelerating factor (DAF), and
[0019] optionally a signal peptide and / or tag;
[0020] Or composed of the above.
[0021] 2. The hybrid protein of embodiment 1, wherein CCP1 and CCP2 of CFH are directly linked together to form CCP1-2.
[0022] 3. The hybrid protein of embodiment 1 or 2, wherein CCP1 of human CFH comprises or consists of the amino acid sequence of positions 19 to 82 of the human CFH protein; and / or CCP2 of human CFH comprises or consists of the amino acid sequence of positions 83 to 143 of the human CFH protein,
[0023] Optionally, the CCP1 comprises a V62I mutation,
[0024] Optionally, the CCP2 comprises one, two or three of E116T, Q119K and V143E mutations,
[0025] The amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO: 3.
[0026] 4. The hybrid protein of embodiment 1 or 2, wherein CCP1-2 of human CFH comprises or consists of the amino acid sequence of positions 19-143 of the human CFH protein,
[0027] Optionally, the CCP1-2 comprises one, two, three or four of the mutations V62I, E116T, Q119K and V143E,
[0028] The amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO: 3.
[0029] 5. The hybrid protein according to any one of embodiments 1-4, wherein CCP4 of human DAF comprises or consists of the amino acid sequence of amino acids 223-285 of the human DAF protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO: 1.
[0030] 6. The hybrid protein according to any one of embodiments 1-4, wherein CCP4 of human DAF comprises or consists of the amino acid sequence of amino acids 223-287 of human DAF protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO: 1.
[0031] 7. The hybrid protein of embodiment 2, wherein
[0032] (1) CCP1 of human CFH comprises or consists of the amino acid sequence of positions 19 to 82 of the human CFH protein, CCP2 of human CFH comprises or consists of the amino acid sequence of positions 83 to 143 of the human CFH protein, and CCP4 of human DAF comprises or consists of the amino acid sequence of positions 223 to 285 of the human DAF protein;
[0033] (2) CCP1 of human CFH comprises or consists of the amino acid sequence of positions 19 to 82 of the human CFH protein, CCP2 of human CFH comprises or consists of the amino acid sequence of positions 83 to 143 of the human CFH protein, and CCP4 of human DAF comprises or consists of the amino acid sequence of positions 223 to 287 of the human DAF protein;
[0034] (3) CCP1-2 of human CFH comprises or consists of the amino acid sequence of positions 19-143 of the human CFH protein, and CCP4 of human DAF comprises or consists of the amino acid sequence of positions 223-285 of the human DAF protein; or
[0035] (4) CCP1-2 of human CFH comprises or consists of the amino acid sequence of positions 19-143 of the human CFH protein, and CCP4 of human DAF comprises or consists of the amino acid sequence of positions 223-287 of the human DAF protein;
[0036] The amino acid positions of the human CFH protein correspond to the amino acid position numbers shown in SEQ ID NO: 3, and the amino acid positions of the human DAF protein correspond to the amino acid position numbers shown in SEQ ID NO: 1.
[0037] 8. The hybrid protein of embodiment 7, wherein CCP1 of human CFH comprises a V62I mutation, CCP2 of human CFH comprises one, two or three of the E116T, Q119K and V143E mutations, and / or CCP1-2 of human CFH comprises one, two, three or four of the V62I mutation, E116T, Q119K and V143E mutations.
[0038] 9. The hybrid protein according to any one of embodiments 1 to 8, wherein the human CFH protein is a human native CFH protein or a protein comprising
[0039] (i) the amino acid sequence shown in SEQ ID NO: 3 or 5,
[0040] (ii) the amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 4 or 6;
[0041] (iii) having at least 95%, 96%, 97%, 98%, or 99% amino acid sequence with the amino acid sequence shown in (i) or (ii);
[0042] Or it may consist of the amino acid sequence shown in any one of (i) to (iii).
[0043] 10. The hybrid protein according to any one of embodiments 1 to 9, wherein the human DAF protein is a human native DAF protein or a protein comprising
[0044] (i) the amino acid sequence shown in SEQ ID NO: 1,
[0045] (ii) the amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 2;
[0046] (iii) having at least 95%, 96%, 97%, 98%, or 99% amino acid sequence with the amino acid sequence shown in (i) or (ii);
[0047] Or it may consist of the amino acid sequence shown in any one of (i) to (iii).
[0048] 11. The hybrid protein according to any one of embodiments 1-10, wherein
[0049] The CCP1 of the human CFH comprises an amino acid sequence of SEQ ID NO: 14 or 15, or comprises an amino acid sequence that is identical to SEQ ID NO: 14 or 15.
[0050] an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% identity to the amino acid sequence of 15, or consisting of said sequence;
[0051] The CCP2 of human CFH comprises the amino acid sequence of SEQ ID NO: 16 or 17, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 16 or 17;
[0052] The CCP1-2 of human CFH comprises the amino acid sequence of SEQ ID NO: 31, 32, 33 or 34, or comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 31, 32, 33 or 34, or consists of the sequence; and / or
[0053] The CCP4 of human DAF comprises the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11, or comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11, or consists of said sequence.
[0054] 12. The hybrid protein according to any one of embodiments 1-11, wherein the tag is, for example, a purification tag, such as a hexahistidine tag or a biotin tag, for example, comprising the amino acid sequence shown in SEQ ID NO: 19.
[0055] 13. The hybrid protein according to any one of embodiments 1-12, wherein the signal peptide is a secretory signal peptide, for example, comprising the amino acid sequence shown in SEQ ID NO: 20.
[0056] 14. The hybrid protein of any one of embodiments 1-13, wherein the hybrid protein comprises the amino acid sequence of any one of SEQ ID NOs: 21-28, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99% identical to said amino acid sequence.
[0057] 15. A hybrid protein comprising
[0058] (i) CCP15 or CCP8 of human complement receptor 1 (CR1),
[0059] (ii) CCP3-4 of human decay accelerating factor (DAF), and
[0060] optionally a signal peptide and / or tag;
[0061] Or composed of the above.
[0062] 16. The hybrid protein of embodiment 15, wherein CCP3 and CCP4 of DAF are directly linked together to form CCP3-4.
[0063] 17. The hybrid protein of embodiment 15 or 16, wherein CCP15 of human CR1 comprises the amino acid sequence of positions 941-1001 of the human CR1 protein, and CCP8 comprises the amino acid sequence of positions 491-551 of the human CR1 protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO:7.
[0064] 18. The hybrid protein according to any one of embodiments 15-17, wherein CCP3 of human DAF comprises or consists of the amino acid sequence of amino acids 161-222 of the human DAF protein, and / or CCP4 of human DAF comprises or consists of the amino acid sequence of amino acids 223-285 of the human DAF protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO: 1.
[0065] 19. The hybrid protein according to any one of embodiments 15-17, wherein CCP3 of human DAF comprises or consists of the amino acid sequence of amino acids 161-222 of the human DAF protein, and / or CCP4 of human DAF comprises or consists of the amino acid sequence of amino acids 223-287 of the human DAF protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO: 1.
[0066] 20. The hybrid protein of embodiment 16 or 17, wherein CCP3-4 of human DAF comprises or consists of the amino acid sequence of positions 161-285 of the human DAF protein, wherein the amino acid positions correspond to the amino acid position numbering shown in SEQ ID NO: 1.
[0067] 21. The hybrid protein of embodiment 16 or 17, wherein CCP3-4 of human DAF comprises or consists of the amino acid sequence of positions 161-287 of the human DAF protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO: 1.
[0068] 22. The hybrid protein of embodiment 16, wherein
[0069] (1) CCP15 of human CR1 comprises or consists of the amino acid sequence of positions 941-1001 of the human CR1 protein, and CCP3 of human DAF comprises or consists of the amino acid sequence of positions 161-222 of the human DAF protein, and CCP4 of human DAF comprises or consists of the amino acid sequence of positions 223-285 of the human DAF protein; or
[0070] (2) CCP15 of human CR1 comprises or consists of the amino acid sequence of positions 941-1001 of the human CR1 protein, and CCP3 of human DAF comprises or consists of the amino acid sequence of positions 161-222 of the human DAF protein, and CCP4 of human DAF comprises or consists of the amino acid sequence of positions 223-287 of the human DAF protein; or
[0071] (3) CCP15 of human CR1 comprises or consists of the amino acid sequence of positions 941-1001 of the human CR1 protein, and CCP3-4 of human DAF comprises or consists of the amino acid sequence of positions 161-285 of the human DAF protein;
[0072] (4) CCP15 of human CR1 comprises or consists of the amino acid sequence of positions 941-1001 of the human CR1 protein, and CCP3-4 of human DAF comprises or consists of the amino acid sequence of positions 161-287 of the human DAF protein;
[0073] The amino acid positions of the human CR1 protein correspond to the amino acid position numbers shown in SEQ ID NO: 7, and the amino acid positions of the human DAF protein correspond to the amino acid position numbers shown in SEQ ID NO: 1.
[0074] 23. The hybrid protein according to any one of embodiments 16-22, wherein the human CR1 protein is a human native CR1 protein or a protein comprising
[0075] (i) the amino acid sequence shown in SEQ ID NO: 7,
[0076] (ii) the amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 8;
[0077] (iii) having at least 95%, 96%, 97%, 98%, or 99% amino acid sequence with the amino acid sequence shown in (i) or (ii);
[0078] Or it may consist of the amino acid sequence shown in any one of (i) to (iii).
[0079] 24. The hybrid protein according to any one of embodiments 15-23, wherein the human DAF protein is a human native DAF protein or a protein comprising
[0080] (i) the amino acid sequence shown in SEQ ID NO: 1,
[0081] (ii) the amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 2;
[0082] (iii) having at least 95%, 96%, 97%, 98%, or 99% amino acid sequence with the amino acid sequence shown in (i) or (ii);
[0083] Or it may consist of the amino acid sequence shown in any one of (i) to (iii).
[0084] 25. The hybrid protein according to any one of embodiments 18-24, wherein
[0085] The CCP15 or CCP8 of human CR1 comprises the amino acid sequence of SEQ ID NO: 18, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 18;
[0086] The CCP3 of human DAF comprises the amino acid sequence of SEQ ID NO: 9, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 9;
[0087] The CCP4 of human DAF comprises the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11;
[0088] The CCP3-4 of human DAF comprises the amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 13, or comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 13, or consists of the sequence.
[0089] 26. The hybrid protein according to any one of embodiments 16-25, wherein the tag is, for example, a purification tag, such as a hexahistidine tag or a biotin tag, for example, comprising the amino acid sequence shown in SEQ ID NO: 19.
[0090] 27. The hybrid protein according to any one of embodiments 16-26, wherein the signal peptide is a secretory signal peptide, for example, it comprises the amino acid sequence shown in SEQ ID NO: 20.
[0091] 28. The hybrid protein of any one of embodiments 16-27, wherein the hybrid protein comprises the amino acid sequence of SEQ ID NO: 29 or 30, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99% identical to said amino acid sequence.
[0092] 29. A nucleic acid molecule encoding the hybrid protein of any one of embodiments 1-28.
[0093] 30. An expression vector comprising the nucleic acid molecule of embodiment 29, preferably, the expression vector is pCDNA3.1.
[0094] 31. A host cell comprising the nucleic acid molecule of embodiment 29 or the expression vector of embodiment 30, preferably, the host cell is prokaryotic or eukaryotic, such as 293 cells, such as Expi293 cells.
[0095] 32. A method for preparing the hybrid protein of any one of embodiments 1-28, comprising culturing the host cell of embodiment 31 under conditions suitable for expression of the hybrid protein, and optionally further comprising isolating the protein from the host cell or the host cell culture medium, and / or purifying the protein.
[0096] 33. A pharmaceutical composition, medicament or formulation comprising the hybrid protein or nucleic acid molecule encoding the same according to any one of embodiments 1 to 28, or the nucleic acid molecule according to embodiment 29, and optionally a pharmaceutically acceptable excipient.
[0097] 34. Drug combination products containing
[0098] The hybrid protein or nucleic acid molecule encoding the same according to any one of embodiments 1 to 28, or the nucleic acid molecule according to embodiment 29; and
[0099] Other therapeutic agents.
[0100] 35. A method for preventing or treating a disease or condition associated with the complement system in a subject, comprising administering to the subject an effective amount of the hybrid protein of any one of embodiments 1-28 or a nucleic acid molecule encoding the same; or the nucleic acid molecule of embodiment 29; or the pharmaceutical composition or formulation of embodiment 33; or the pharmaceutical combination product of embodiment 34.
[0101] 36. The method of embodiment 35, wherein the disease or disorder is due to abnormal activation of the complement system or dysregulation of the complement system.
[0102] 37. The method according to embodiment 36, wherein the abnormal activation of the complement system or the dysregulation of the complement system is due to, for example, microbial infection or an increase in autoimmune antibodies, or is due to a decrease, loss, disability or functional interference or blockage of complement regulatory proteins. 38. The method according to embodiment 37, wherein the complement system-related disease or disorder is selected from diseases caused by activation of the alternative pathway, such as diseases that require inhibition of the complement immune alternative pathway and optionally do not inhibit the complement immune classical pathway, such as paroxysmal nocturnal hemoglobinuria. BRIEF DESCRIPTION OF THE DRAWINGS
[0103] FIG1 shows the crystal structures of the CCP1-4 domain of CFH protein and DAF protein (with CCP1-4 domain), and the structural model of the biased hybrid protein F12D4 (constructed from CFH CCP1-2 and DAF CCP4).
[0104] FIG2 shows reducing and non-reducing SDS-PAGE electrophoresis images of various recombinant complement regulatory proteins constructed according to the present invention after expression in Expi293 cells. The legend indicates the protein types in each lane.
[0105] FIG3 shows the purity results of the biased hybrid protein F12D4 detected by HPLC-SEC.
[0106] FIG4 shows the purity results of the biased hybrid protein CR15D34 (constructed from CR1CCP15 and DAF CCP3-4) detected by HPLC-SEC.
[0107] FIG5 shows the CP inhibitory activity of various complement regulatory proteins.
[0108] FIG6 shows the AP inhibitory activity of various complement regulatory proteins.
[0109] Detailed Description of the Invention
[0110] I. Definitions:
[0111] It should be understood that the present invention is not limited to the specific methodologies, protocols, and reagents described herein, as these may vary. It should also be understood that the terms used herein are for the purpose of describing specific embodiments only, and are not intended to limit the scope of the present invention, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the present invention belongs.
[0112] Decay Accelerating Factor (DAF)
[0113] Decay-accelerating factor (DAF, CD55) is a membrane-associated regulatory protein that protects cells from autologous complement activation on their surface. DAF acts by rapidly dissociating the C3 and C5 convertases, the central enzymes of the cascade. DAF possesses the most potent decay-accelerating activity of proteins involved in complement regulation and acts on both the classical pathway (C4b2a and C4b2a3b) and alternative pathway (C3bBb and C3BbC3b) enzymes. However, DAF does not function as a cofactor.
[0114] The structural analysis of DAF shows that it consists of four It consists of a 60-amino acid unit, followed by a segment (STP) rich in heavily O-glycosylated serine (S) and threonine (T), followed by a post-translationally added glycoinositide phospholipid (GPI) anchor.
[0115] In some embodiments, the DAF is human DAF having the following accession numbers: Genbank Accession No. M31516, M15799, M64653, S72858, or M643567.
[0116] In some embodiments, DAF is human DAF. In some embodiments, human DAF is human native DAF. In some embodiments, the amino acid sequence of human native DAF is shown in SEQ ID NO: 1, and its various modules are shown in Table 1 below. The four 60-amino acid long repeating units are called complement control protein repeats (CCPs) or short consensus repeats (SCRs). CCP1 includes amino acids 35-96. CCP2 includes amino acids 96-160; CCP3 includes amino acids 161-222, and CCP4 includes amino acids 223-285. They provide all the regulatory activities of DAF. The highly O-glycosylated region acts as a buffer zone, which positions the CCP at an appropriate distance above the surface membrane. The GPI anchor allows DAF to move freely within the plane of the plasma membrane, enabling it to inactivate the invertase complex anywhere the invertase complex is assembled. In this article, when referring to the amino acid positions of the modules of DAF, they are all numbered corresponding to the amino acid positions shown in SEQ ID NO: 1.
[0117] In some embodiments, the amino acid positions corresponding to the modules of DAF are shown in Table 1 below. In some embodiments, where the context otherwise defines, the amino acid positions corresponding to the modules of DAF are adjusted based on the sites marked in Table 1 (e.g., truncated or extended by 1-2 amino acid residues in the N-terminal and / or C-terminal directions).
[0118] Table 1: Protein modules of DAF (UniProt classification)
[0119] In some embodiments, the nucleotide sequence of the cDNA encoding DAF is shown in SEQ ID NO:2.
[0120] Factor H (CFH or FH)
[0121] "Complement factor H," "Factor H," "FH," "CFH protein," or "CFH" are used interchangeably and refer to a protein of approximately 150 kDa that is a member of the regulators of complement activation family and a complement control protein. CFH is a large, soluble glycoprotein that circulates in human plasma and serves to regulate the alternative pathway of the complement system, ensuring that the complement system is directed against pathogens or other dangerous substances and does not damage host tissues.
[0122] Factor H is primarily a monomer, but its self-association is weak (KD = 28 μM) and it may oligomerize in the presence of glycosaminoglycans or high concentrations of metal ions. CFH is composed of 20 homologous units called complement control protein repeats (CCPs) (SCRs or sushi domains), some of which function in cell attachment, while others eliminate C3b from the cell surface. Each of the 20 SCRs is approximately 60 amino acids long, arranged in a head-to-tail pattern, and contains four cysteine residues, with each module forming two disulfide bonds. SCRs 19 and 20 are involved in C3b binding.
[0123] The splice variant FHL-1 consists of the first 7 CCPs followed by the C-terminal sequence Ser-Pro-Leu-Thr. Each CCP contains approximately 60 residues, including four invariant cysteines forming the Cys I -Cys III 、Cys II -Cys IV Disulfides. Adjacent modules are linked by sequences of three to eight residues.
[0124] In negative-stain electron micrographs, the FH molecule adopts multiple conformations, but is predominantly folded in half; analytical ultracentrifugation, small-angle X-ray scattering (modules deposited in the PDB, e.g., 3GAV), and chemical cross-linking also indicate that the module chains themselves are bent. The high-resolution structures of several FH fragments, alone or in complex with other molecules, have been determined (PDB identifiers are provided in parentheses): CCPs 1-2 (2RLP), 2-3 (2RLQ), 1-4 (2WII), 5, 6-7 (e.g., 2W80, 2YBY), 7 (2JGW and 2JGX), 6–8 (2UWN and 2V8E), 9 (4K12), 10-11 (4B2R), 11-12 (4B2S), 12-13 (2KMS), 15 (1HFI), 16 (1HCC), 15-16 (1HFH), 18-20 (3SWO), and 19-20 (e.g., 2BZM, 2G7I, and 4ONT). Each CCP resembles a prolate spheroid with a major axis of approximately 4 nm and a minor axis of approximately 2 nm, and contains β-strands arranged in antiparallel sheets that are roughly aligned with the major axis. Its N- and C-termini are located at either end of its long axis, promoting end-to-end arrangements of tandem CCPs with variable intermodule contacts, tilts, and twists.
[0125] In some embodiments, CFH is human CFH, such as human native CFH. In some embodiments, the amino acid sequence of CFH has the following accession numbers: HGNC:HGNC:4883, Ensembl:ENSG00000000971, HPRD:00601, MIM:134370, or Vega:OTTHUMG00000035607.
[0126] In some embodiments, the amino acid sequence of CFH is as shown in SEQ ID NO: 3. In some embodiments, the amino acid positions corresponding to the various modules of CFH are shown in Table 2 below. In some embodiments, where the context otherwise defines, the amino acid positions corresponding to the various modules of CFH are adjusted based on the sites marked in Table 2 (e.g., truncated or extended by 1-2 amino acid residues in the N-terminal and / or C-terminal directions).
[0127] Table 2: Protein modules of CFH (Uniprot classification)
[0128] In some embodiments, the nucleotide sequence of the cDNA encoding CFH is shown in SEQ ID NO:4.
[0129] In some embodiments, the protein sequence encoding the splice variant of CFH, FHL-1, is shown in SEQ ID NO: 5. In some embodiments, the nucleotide sequence of the cDNA encoding the splice variant of CFH, FHL-1, is shown in SEQ ID NO: 6.
[0130] In this document, when referring to the amino acid positions of the CFH module, they are all numbered corresponding to the amino acid positions shown in SEQ ID NO:3.
[0131] Complement receptor 1 (CR1)
[0132] "Complement receptor type 1," "CR1," or "CD35" are used interchangeably and refer to the complement C3b / C4d receptor membrane protein of the complement activating receptor family. Its most common splice, CR1isoform F precursor, consists of 2039 amino acids and has a molecular weight of approximately 220 kD. CR1 is primarily expressed on erythrocytes, monocytes, macrophages, neutrophils, and B cells, but is also present on some T lymphocytes, mast cells, and glomerular podocytes. As its name suggests, the primary ligand for CR1 is C3b / C4d, which mediates complement opsonization and promotes immune complex clearance. CR1 has been shown to act as a negative regulator of the complement cascade, mediating immune adhesion and phagocytosis and inhibiting both the classical and alternative pathways.
[0133] Taking its most common spliceosome as an example, the full-length CR1 protein comprises a 42-amino acid signal peptide, a 1930-amino acid extracellular domain, a 25-amino acid transmembrane domain, and a 43-amino acid C-terminal cytoplasmic domain. The CR1 extracellular domain has 25 potential N-glycosylation signal sequences and contains 30 CCP domains, each approximately 60-70 amino acids long. The sequence homology between these CCPs ranges from 60-99%.
[0134] In some embodiments, CR1 is human CR1, such as human native CR1. In some embodiments, the amino acid sequence of CFH has the following accession numbers: Uniprot Accession No. P17927, Genbank Accession Nos. NP_000564.2, NP_000642.3, and NP_001368780.1.
[0135] In some embodiments, the amino acid sequence of CR1 is as shown in SEQ ID NO: 7. In some embodiments, the amino acid positions corresponding to the various modules of CR1 are shown in Table 3 below. In some embodiments, the amino acid positions corresponding to the various modules of CR1 are adjusted based on the sites marked in Table 3 (e.g., truncated or extended by 1-2 amino acid residues in the N-terminal and / or C-terminal direction) when the context otherwise defines.
[0136] Table 3: Protein modules of CR1 (Uniprot classification)
[0137] In some embodiments, the nucleotide sequence of the cDNA encoding CR1 is shown in SEQ ID NO:8.
[0138] When referring to the amino acid positions of the CR1 module herein, the amino acid positions are numbered corresponding to the amino acid positions shown in SEQ ID NO:7.
[0139] Other definitions
[0140] To interpret this specification, the following definitions will apply, and wherever appropriate, terms used in the singular may also include the plural, and vice versa. It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[0141] The term "about" when used in conjunction with a numerical value is meant to encompass the numerical value within a range having a lower limit that is 5% less than the specified numerical value and an upper limit that is 5% greater than the specified numerical value.
[0142] As used herein, the term "and / or" means any one of the alternatives or two or more or all of the alternatives.
[0143] As used herein, the terms "comprising" or "including" are intended to include the recited elements, integers, or steps, but not to exclude any other elements, integers, or steps. In this document, when the terms "comprising" or "including" are used, unless otherwise indicated, the context also encompasses consisting of the recited elements, integers, or steps. For example, when reference is made to a protein "comprising" a particular sequence, it is intended to encompass a protein consisting of that particular sequence.
[0144] The terms "protein" and "polypeptide" are used interchangeably herein to refer to a polymer sequence comprising amino acid residues. Unless otherwise specified, the single-letter and three-letter codes for amino acids as defined by the IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) are used herein. The single letter X refers to any of the twenty amino acids. It is also understood that due to the degeneracy of the genetic code, a polypeptide may be encoded by more than one nucleotide sequence.
[0145] As used herein, the terms "hybrid protein" and "chimeric polypeptide" are used interchangeably to refer to a polypeptide formed by the fusion of at least two heterologous polypeptide sequences, optionally via a linker. Hybrid proteins can be produced by recombinant expression.
[0146] "Percent (%) identity" of an amino acid sequence refers to the percentage of amino acid residues in the candidate sequence that are identical to the amino acid residues in the specific amino acid sequence set forth in this specification, after aligning the candidate sequence with the specific amino acid sequence set forth in this specification and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. In some embodiments, the present invention contemplates variants of the proteins or polypeptides of the present invention that have a substantial degree of identity, e.g., at least 80%, 85%, 90%, 95%, 97%, 98%, or 99% or more, to the polypeptides or proteins specifically disclosed herein. Such variants may comprise conservative changes.
[0147] For polypeptide sequences, "conservative changes" include replacements, deletions, or additions to the polypeptide sequence that do not substantially change the desired functional activity of the polypeptide sequence. For example, conservative substitutions often result in a substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. The following lists 8 groups of amino acids containing conservative substitutions for each other: 1) alanine (A), glycine (G); 2) aspartic acid (D), glutamic acid (E); 3) asparagine (N), glutamine (Q); 4) arginine (R), lysine (K); 5) isoleucine (I), leucine (L), methionine (M), valine (V); 6) phenylalanine (F), tyrosine (Y), tryptophan (W); 7) serine (S), threonine (T); and 8) cysteine (C), methionine (M). In some embodiments, the term "conservative sequence change" is used to refer to amino acid modifications that do not significantly affect or change the activity of the parent hybrid protein. For example, conservatively modified variants maintain at least 80%, 85%, 90%, 95%, 98%, 99% or higher, such as 100-110% or higher activity relative to the parent polypeptide or hybrid protein. In this article, as used by those skilled in the art, the mutation / replacement in the amino acid sequence can be named as follows: the single-letter code of the parent amino acid, followed by the position number, followed by the single-letter code of the variant amino acid. For example, the mutation of valine (V) at position 62 to isoleucine (I) is represented as "V62I", wherein, unless otherwise clearly defined or stated, the position number is generally with reference to the position number of the native full-length polypeptide / protein (even if it refers to the position in the fragment / truncation), such as the position number of the most common spliceosome form.
[0148] The term "host cell" refers to a cell into which an exogenous polynucleotide has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and the progeny derived therefrom. Host cells are any type of cell system that can be used to produce the hybrid protein of the present invention, including eukaryotic cells, e.g., mammalian cells, insect cells, yeast cells; and prokaryotic cells, e.g., E. coli cells. Host cells include cultured cells, as well as cells within transgenic animals, transgenic plants, or cultured plant tissues or animal tissues.
[0149] The term "expression vector" refers to a vector comprising a recombinant polynucleotide comprising an expression control sequence operatively linked to a nucleotide sequence to be expressed. The expression vector comprises sufficient cis-acting elements for expression; other elements for expression may be provided by the host cell or in an in vitro expression system. Expression vectors include all those known in the art, including cosmids, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) into which the recombinant polynucleotide is incorporated.
[0150] The terms "classical pathway" and "CP" refer to one of the activation pathways of the complement system. As is known in the art, generally speaking, the complement system of higher mammals (such as Homo sapiens) has three activation pathways: the classical pathway, the alternative pathway (or bypass pathway), and the lectin pathway. The classical pathway is activated by the binding of corresponding activating factors (mainly antigen-antibody complexes) to C1. C1q binds to a single IgM molecule or two adjacent IgG molecules, for example, an IgG "doublet" binds to an antigen, and reacts with C1q to activate C1, which in turn activates C1r and C1s, and then activates downstream complement molecules in a cascade and amplified manner through the cascade reaction sequence of C1, 4, 2, 3, 5, 6, 7, 8, and 9 of the classical complement activation pathway, wherein C3 is catalytically cleaved by the classical pathway C3 convertase C4b2a to produce C3b, which then reacts with C4b2a to form the classical pathway C5 convertase: C4b2a3b, which catalyzes the cleavage of C5 to produce C5b. C5b binds to C6 and C7 to form the C5b67 complex, which ultimately joins with C8 and C9 molecules to form the C5b6789 complex, the membrane-attacking complex. This complex creates a 10nm pore in the cell membrane, causing the target cell to swell and rupture due to an inability to maintain osmotic pressure. C3 convertase catalyzes the cleavage of C3 to produce C3b, a common downstream pathway in the complement activation pathway.
[0151] The term "alternative pathway," or "alternative pathway," or "AP" refers to one of the complement system activation pathways. Unlike the classical pathway, which often requires the intervention of a specific immune response (antigen-antibody complex), in the alternative pathway, activated by substances such as bacterial cell walls, polysaccharides, peptidoglycan, teichoic acid, and aggregated IgA and IgG4, C3 spontaneously cleaves to form C3b, which is then combined with factors B, D, and P to form the C3 convertase, which then accumulates to a certain level and triggers the downstream cascade reaction.
[0152] The terms "individual" or "subject" are used interchangeably and refer to mammals. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In particular, the individual is a human.
[0153] The term "treating" includes administering a composition or hybrid polypeptide to prevent or delay the onset of symptoms, complications, or biochemical indicators of a disease, to alleviate symptoms, or to arrest or inhibit further development of a disease, condition, or disorder. The term "preventing" includes inhibiting the onset or development of a disease or disorder or symptoms of a particular disease or disorder.
[0154] The term "pharmaceutical excipient" refers to a diluent, adjuvant (eg, Freund's adjuvant (complete and incomplete)), excipient, carrier, stabilizer, or the like, which is administered together with the active substance.
[0155] The term "pharmaceutical composition" refers to a composition that is in form permitting the biological activity of the active ingredient contained therein to be effective, and that contains no additional ingredients that are unacceptably toxic to a subject to which the composition would be administered.
[0156] The term "effective amount" refers to the amount or dosage of the hybrid protein of the present invention or the nucleic acid encoding the same or the composition or combination thereof, which produces the desired effect in a patient in need of treatment or prevention after administration in single or multiple doses to the patient.
[0157] A "therapeutically effective amount" is an amount effective to achieve the desired therapeutic outcome at the desired dosage and for the desired period of time. A therapeutically effective amount is also one in which any toxic or deleterious effects of the hybrid protein, composition, or combination are outweighed by the therapeutically beneficial effects. A "therapeutically effective amount" preferably inhibits a measurable parameter or improves a measurable parameter by at least about 40%, even more preferably by at least about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or even 100%, relative to an untreated subject.
[0158] A "prophylactically effective amount" refers to an amount effective to achieve the desired preventive result, at the required dosage and for the required period of time. Typically, a prophylactic amount will be less than a therapeutically effective amount because a prophylactic dose is used in a subject prior to or at an earlier stage of disease.
[0159] These and other aspects and embodiments of the present invention are described in the accompanying drawings (a brief description of the drawings follows) and the following detailed description of the invention and are exemplified in the following examples. Any or all of the features discussed above and throughout this application may be combined in various embodiments of the present invention. The following examples further illustrate the present invention, however, it should be understood that the examples are described in an illustrative and non-limiting manner, and that various modifications may be made by those skilled in the art.
[0160] II. Hybrid Protein
[0161] The present invention relates to a hybrid protein of CFH and DAF, which comprises at least one functional unit derived from CFH and at least one functional unit derived from DAF.
[0162] A.DAF functional unit
[0163] In certain embodiments, the hybrid proteins of the present invention preferably comprise a functional unit from DAF. Such a functional unit is capable of dissociating C3 and C5 convertases and / or accelerating decay-accelerating activity against the classical pathway C3 convertase and / or the alternative pathway C3 convertase. In some embodiments, the DAF functional unit comprises CCP 4 of DAF. In some embodiments, the DAF functional unit comprises CCPs 3 and 4 of DAF.
[0164] The amino acid sequence of such a CCP can be identical to the native or naturally occurring amino acid sequence of DAF. Alternatively, the amino acid sequence of such a CCP can be slightly altered, particularly at the amino or carboxyl termini. Such alterations can occur when restriction enzyme sites are incorporated into the polynucleotide encoding the CCP. Such alterations can also occur when amino acids are deleted from the N-terminus or C-terminus of the functional unit. For example, in some embodiments, 1-2 amino acids can be deleted from the N-terminus of CCP3.
[0165] Some amino acid substitutions, preferably conservative substitutions, in the sequence can also be introduced without affecting functional activity. Conservative substitutions can be, for example, substitutions of charged amino acids with one another or substitutions of hydrophilic amino acids with one another, substitutions of hydrophobic amino acids with one another, and substitutions of amino acids of similar mass with one another.
[0166] In some embodiments, the DAF functional unit comprises at least 95%, 96%, 97%, 98%, or 99% of the amino acid sequence of CCP4 of the human DAF protein. In some embodiments, the DAF functional unit comprises CCP4 of the human DAF protein. In some embodiments, the DAF functional unit comprises at least 95%, 96%, 97%, 98%, or 99% of the amino acid sequence of CCP 3 and / or 4 of the human DAF protein (or CCP3-4 directly linked by the C-terminus of CCP3 and the N-terminus of CCP4). In some embodiments, the DAF functional unit comprises CCP3 and / or 4 of the human DAF protein (CCP3-4 directly linked by the C-terminus of CCP3 and the N-terminus of CCP4). In some embodiments, the DAF functional unit includes CCP3 and 4 of the human DAF protein. In some embodiments, the DAF functional unit is CCP3-4 directly linked by the C-terminus of CCP3 and the N-terminus of CCP4.
[0167] In some embodiments, the human DAF protein is a native human DAF protein. In some embodiments, the native human DAF protein comprises or consists of the amino acid sequence shown in SEQ ID NO: 1. DAF comprises or consists of the amino acid sequence encoded by the DNA sequence shown in SEQ ID NO: 2.
[0168] In some embodiments, CCP3 comprises or consists of amino acids 161 to 222 of DAF.
[0169] In some embodiments, CCP3 comprises the amino acid sequence of SEQ ID NO:9, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO:9.
[0170] SEQ ID NO:9:
[0171] In some embodiments, CCP4 comprises or consists of amino acids 223 to 285 of DAF. In some embodiments, in order to connect other functional units, the C-terminus of CCP4 can be extended to include an additional 1-2 amino acids, such as 1-2 adjacent amino acids, for example, CCP4 comprises or consists of amino acids 223 to 287 of DAF.
[0172] In some embodiments, CCP4 comprises the amino acid sequence of SEQ ID NO: 10, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 10 or 11.
[0173] SEQ ID NO: 10:
[0174] SEQ ID NO:11:
[0175] In some embodiments, CCP3-4 comprises or consists of amino acids 161 to 285 or amino acids 161 to 287 of DAF. In some embodiments, the DAF functional unit CCP3-4 comprises or consists of the amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 13, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 13.
[0176] SEQ ID NO: 12: Human DAF CCP3-4
[0177] SEQ ID NO: 13: Human DAF CCP3-4 (CCP4 C-terminus extended by 2 amino acids)
[0178] When referring to amino acid positions of DAF, the amino acid sequence positions correspond to the amino acid positions of SEQ ID NO: 1.
[0179] B.CFH functional unit
[0180] In certain embodiments, the hybrid protein of the present invention comprises a functional unit from CFH. Such a functional unit is capable of dissociating the alternative pathway C3 convertase C3bBb and / or binding to C3b. In a preferred embodiment, the CFH functional unit comprises CCP1 and 2 of CFH.
[0181] The amino acid sequence of the CCP of such a CFH can be identical to the native or naturally occurring amino acid sequence of the CFH. Alternatively, the amino acid sequence of such a CCP can be slightly altered, particularly at the amino or carboxyl termini. Such alterations can occur when restriction enzyme sites are incorporated into the polynucleotide encoding the CCP. Such alterations can also occur when amino acids are deleted or added from the N-terminus or C-terminus of the functional unit.
[0182] For example, in some embodiments, 1-2 amino acids can be deleted at the N-terminus of CCP1. In some embodiments, 1-2 amino acids can be deleted at the C-terminus of CCP2. In some embodiments, the N-terminus and / or C-terminus of CCP1 and / or CCP2 can also be extended, for example, by adding 1-2 adjacent amino acids, for connecting other functional units or sequences. Therefore, "CCP1" and "CCP2" described herein respectively encompass CCP1 and CCP2 with added amino acids (e.g., 1-2 adjacent amino acids) at the N-terminus and / or C-terminus.
[0183] It is also possible to introduce some amino acid substitutions into the sequence without affecting the functional activity, preferably conservative substitutions. Conservative substitutions can be, for example, replacing charged amino acids with one another, or replacing hydrophilic amino acids with one another, replacing hydrophobic amino acids with one another, or replacing amino acids of similar mass with one another. For example, the CCP1 of the CFH of the present invention can include a V62I mutation. For example, the CCP2 of the CFH of the present invention can include one, two, or three of the E116T, Q119K, and V143E mutations.
[0184] In one embodiment, the CFH functional unit comprises an amino acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to CCP 1 of a human CFH protein. In some embodiments, the CFH functional unit comprises CCP 1 of a human CFH protein. In one embodiment, the CFH functional unit comprises an amino acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to CCP 2 of a human CFH protein. In some embodiments, the CFH functional unit comprises CCP 2 of a human CFH protein. In one embodiment, the CFH functional unit comprises an amino acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to CCP 1 and / or 2 of a human CFH protein (or CCP 1-2 directly linked by the C-terminus of CCP 1 to the N-terminus of CCP 2). In some embodiments, the CFH functional unit comprises CCP 1 and / or 2 of a human CFH protein (CCP 1-2 directly linked by the C-terminus of CCP 1 to the N-terminus of CCP 2). In some embodiments, the CFH functional unit comprises CCP1 and 2 of the human CFH protein. In some embodiments, the CFH functional unit is CCP1-2 directly linked by the C-terminus of CCP1 and the N-terminus of CCP2.
[0185] In some embodiments, the human CFH protein is a native human CFH protein. In some embodiments, the native human CFH protein comprises or consists of the amino acid sequence shown in SEQ ID NO: 3 or 5. In some embodiments, CFH comprises or consists of the amino acid sequence encoded by the DNA sequence shown in SEQ ID NO: 4 or 6.
[0186] In some embodiments, CCP1 comprises or consists of amino acids 19 to 82 of CFH, optionally wherein CCP1 comprises a V62I mutation. In some embodiments, CCP1 comprises the amino acid sequence of SEQ ID NO: 14 or 15, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 14 or 15, optionally wherein CCP1 comprises a V62I mutation.
[0187] SEQ ID NO: 14: Human CFH CCP1
[0188] SEQ ID NO: 15: Human CFH CCP1 (CCP1 contains V62I)
[0189] In some embodiments, CCP2 comprises or consists of amino acids 83 to 143 of CFH, optionally comprising one, two, or three of E116T, Q119K, and V143E mutations. In some embodiments, CCP2 comprises the amino acid sequence of SEQ ID NO: 16 or 17, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 16 or 17, optionally comprising one, two, or three of E116T, Q119K, and V143E mutations.
[0190] SEQ ID NO: 16: Human CFH CCP2
[0191] SEQ ID NO: 17: Human CFH CCP2 comprising E116T, Q119K and V143E
[0192] When referring to amino acid positions of CFH, the amino acid sequence positions correspond to the amino acid positions of SEQ ID NO:3.
[0193] In some embodiments, CCP1-2 comprises or consists of amino acids 19 to 143 of CFH, optionally CCP1-2 comprises one, two, three, or four of the V62I, E116T, Q119K, and V143E mutations. In some embodiments, CCP1-2 comprises the amino acid sequence of any one of SEQ ID NOs: 31-34, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 31-34.
[0194] >Human CFHCCP1-2 (SEQ ID NO: 31)
[0195] >Human CFHCCP1-2, comprising the point mutation V62I (SEQ ID NO: 32)
[0196] >Human CFHCCP1-2, containing three point mutations E116T, Q119K and V143E (SEQ ID NO: 33)
[0197] >Human CFHCCP1-2, comprising point mutations V62I, E116T, Q119K, and V143E (SEQ ID NO: 34)
[0198] C.CR1 functional unit
[0199] In certain embodiments, the hybrid proteins of the present invention preferably comprise a functional unit from CR1. Such a functional unit is capable of dissociating the C3 and C5 convertases and / or accelerating the decay-accelerating activity against the alternative pathway C3 convertase. In some embodiments, the CR1 functional unit comprises CCP15 or CCP8 of CR1.
[0200] The amino acid sequence of the CCP of such a CR1 may be identical to the native or naturally occurring amino acid sequence of CR1. Alternatively, the amino acid sequence of such a CR1 may be slightly altered, particularly at the amino or carboxyl termini. Such alterations may occur when restriction enzyme sites are incorporated into the polynucleotide encoding the CCP. Such alterations may also occur when amino acids are deleted or added from the N-terminus or C-terminus of the functional unit.
[0201] For example, in some embodiments, 1-2 amino acids can be deleted from the N-terminus or C-terminus of CCP15 or CCP8. In some embodiments, the N-terminus or C-terminus of CCP15 or CCP8 can be extended by 1-2 amino acids, for example, by adding additional adjacent amino acid residues.
[0202] Some amino acid substitutions, preferably conservative substitutions, in the sequence can also be introduced without affecting functional activity. Conservative substitutions can be, for example, substitutions of charged amino acids with one another or substitutions of hydrophilic amino acids with one another, substitutions of hydrophobic amino acids with one another, and substitutions of amino acids of similar mass with one another.
[0203] In one embodiment, the CR1 functional unit comprises an amino acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to CCP 15 or CCP 8 of the human CR1 protein. In some embodiments, the CR1 functional unit comprises CCP 15 or CCP 8 of the human CR1 protein.
[0204] In some embodiments, the human CR1 protein is a native human CR1 protein. In some embodiments, the native human CR1 protein comprises or consists of the amino acid sequence set forth in SEQ ID NO: 7. In some embodiments, CR1 comprises or consists of the amino acid sequence encoded by the DNA sequence set forth in SEQ ID NO: 8.
[0205] In some embodiments, CCP15 comprises or consists of amino acids 941 to 1001 of CR1, or CCP8 comprises or consists of amino acids 491 to 551 of CR1.
[0206] In some embodiments, the CR1 functional unit comprises the amino acid sequence of SEQ ID NO: 18, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 18.
[0207] SEQ ID NO: 18: Human CR1CCP15 or CCP8
[0208] When referring to amino acid positions of CR1, the amino acid sequence positions correspond to the amino acid positions of SEQ ID NO:7.
[0209] D. Other units
[0210] Optionally, the hybrid protein of the present invention may further include a tag, preferably about 2 to 10 amino acids, which is added to the amino or carboxyl terminus, such as the carboxyl terminus, of the hybrid protein. Typically, such additions are performed to stabilize the protein or facilitate secretory expression or purification of the hybrid protein. Such tags are known in the art. Representative examples of such tags include sequences encoding a series of histidine residues (e.g., 2-10 histidines, such as 2, 3, 4, 5, 6, or 7 histidines), epitope tags FLAG, herpes simplex glycoprotein D, β-galactosidase, maltose binding protein, or glutathione S-transferase.
[0211] In some embodiments, the tag is a histidine residue, which can be added to the amino terminus or carboxyl terminus of the hybrid protein, such as the carboxyl terminus.
[0212] In some embodiments, the tag is a 6xHis tag of GHHHHHH (SEQ ID NO: 19).
[0213] Optionally, the hybrid protein of the present invention may further comprise a signal peptide, such as MGWSCIILFLVATATGVHS (SEQ ID NO: 20).
[0214] The present invention also encompasses hybrid proteins in which one or more amino acids are altered by post-translational processes or synthetic methods. Examples of such modifications include, but are not limited to, glycosylation, iodination, myristoylation, and pegylation.
[0215] E. Examples of Hybrid Proteins
[0216] In some embodiments, the hybrid protein of the invention comprises at least one functional unit from CFH and at least one functional unit from DAF.
[0217] In some embodiments, the hybrid protein of the present invention comprises CCP1 and CCP2 of CFH and CCP4 of DAF. In some embodiments, the hybrid protein of the present invention consists of CCP1 and CCP2 of CFH and CCP4 of DAF. In some embodiments, the hybrid protein of the present invention comprises or consists of CCP1-2 of CFH and CCP4 of DAF.
[0218] In some embodiments, CCP1 of the CFH of the present invention may comprise a V62I mutation. In some embodiments, CCP2 of the CFH of the present invention may comprise one, two, or three of E116T, Q119K, and V143E mutations.
[0219] In some embodiments, the hybrid protein of the present invention further comprises a signal peptide at its N-terminus, such as the amino acid sequence shown in SEQ ID NO: 20, and / or a tag at its C-terminus, such as a histidine tag, such as a 6×His tag, such as GHHHHHH (SEQ ID NO: 19).
[0220] In some embodiments, CCP4 of DAF comprises or consists of amino acids 223-285 of the DAF protein, wherein the amino acid positions are numbered corresponding to the amino acid positions set forth in SEQ ID NO: 1. In some embodiments, CCP4 of DAF is extended by two amino acids at its C-terminus, e.g., comprises or consists of amino acids 223-287 of the DAF protein, wherein the amino acid positions are numbered corresponding to the amino acid positions set forth in SEQ ID NO: 1.
[0221] In some embodiments, CCP1 of CFH comprises or consists of amino acids 19-82 of the CFH protein, wherein the amino acid positions correspond to the numbering of amino acid positions as set forth in SEQ ID NO: 3, and optionally CCP1 comprises a V62I mutation. In some embodiments, CCP2 of CFH comprises or consists of amino acids 83-143 of the CFH protein, wherein the amino acid positions correspond to the numbering of amino acid positions as set forth in SEQ ID NO: 3, and optionally CCP2 comprises one, two, or three of E116T, Q119K, and V143E mutations.
[0222] In some embodiments, CCP4 of DAF comprises or consists of amino acids 223-285 of the DAF protein, wherein the amino acid positions correspond to the amino acid position numbering set forth in SEQ ID NO: 1; and CCP1 of CFH comprises or consists of the amino acid sequence of positions 19-82 of the human CFH protein, and CCP2 of CFH comprises or consists of the amino acid sequence of positions 83-143 of the human CFH protein, wherein optionally, the CCP1 comprises a V62I mutation, wherein optionally, the CCP2 comprises one, two or three of E116T, Q119K and V143E mutations, wherein the amino acid positions correspond to the amino acid position numbering set forth in SEQ ID NO: 3.
[0223] In some embodiments, CCP4 of DAF comprises or consists of amino acids 223-287 of the DAF protein, wherein the amino acid positions correspond to the numbering of amino acid positions set forth in SEQ ID NO: 1; and CCP1 of CFH comprises or consists of the amino acid sequence of positions 19-82 of the human CFH protein, and CCP2 of CFH comprises or consists of the amino acid sequence of positions 83-143 of the human CFH protein, wherein optionally, the CCP1 comprises a V62I mutation, wherein optionally, the CCP2 comprises one, two or three of E116T, Q119K and V143E mutations, wherein the amino acid positions correspond to the numbering of amino acid positions set forth in SEQ ID NO: 3.
[0224] In some embodiments, CCP4 of DAF comprises or consists of amino acids 223-285 of the DAF protein, wherein the amino acid positions correspond to the amino acid position numbering set forth in SEQ ID NO: 1; and CCP1-2 of CFH comprises or consists of the amino acid sequence of positions 19-143 of the human CFH protein, wherein optionally, the CCP1-2 comprises one, two, three or four of the mutations V62I, E116T, Q119K and V143E, wherein the amino acid positions correspond to the amino acid position numbering set forth in SEQ ID NO: 3.
[0225] In some embodiments, CCP4 of DAF comprises or consists of amino acids 223-287 of the DAF protein, wherein the amino acid positions correspond to the amino acid position numbering set forth in SEQ ID NO: 1; and CCP1-2 of CFH comprises or consists of the amino acid sequence of positions 19-143 of the human CFH protein, wherein optionally, the CCP1-2 comprises one, two, three or four of the mutations V62I, E116T, Q119K and V143E, wherein the amino acid positions correspond to the amino acid position numbering set forth in SEQ ID NO: 3.
[0226] In some embodiments, the hybrid protein of the present invention comprises CCP15 or CCP8 of CR1 and CCP3 and CCP4 of DAF. In some embodiments, the hybrid protein of the present invention consists of CCP15 or CCP8 of CR1 and CCP3 and CCP4 of DAF. In some embodiments, the hybrid protein of the present invention comprises or consists of CCP15 or CCP8 of CR1 and CCP3-4 of DAF.
[0227] In some embodiments, the hybrid protein of the present invention further comprises a signal peptide at its N-terminus, such as the amino acid sequence shown in SEQ ID NO: 13, and / or a tag at its C-terminus, such as a histidine tag, such as a 6×His tag, such as GHHHHHH.
[0228] In some embodiments, CCP15 of CR1 comprises or consists of amino acids 941-1001 of the CFH protein, or CCP8 comprises or consists of amino acids 491-551 of the CFH protein, wherein the amino acid positions correspond to the amino acid position numbering set forth in SEQ ID NO:3.
[0229] In some embodiments, CCP3 of DAF comprises or consists of amino acids 161-222 of the DAF protein and / or CCP4 comprises or consists of amino acids 223-285 of the DAF protein, wherein the amino acid positions are numbered corresponding to the amino acid positions set forth in SEQ ID NO: 1. In some embodiments, CCP3-4 of DAF comprises or consists of amino acids 161-285 of the DAF protein, wherein the amino acid positions are numbered corresponding to the amino acid positions set forth in SEQ ID NO: 1. In some embodiments, CCP4 of DAF is extended at its C-terminus by two amino acids, e.g., comprises or consists of amino acids 223-287 of the DAF protein, and / or CCP3 comprises or consists of amino acids 161-222 of the DAF protein, wherein the amino acid positions are numbered corresponding to the amino acid positions set forth in SEQ ID NO: 1. In some embodiments, CCP3-4 of DAF is extended at its C-terminus by two amino acids, e.g., comprises or consists of amino acids 161-287 of the DAF protein.
[0230] In some embodiments, CCP3-4 of DAF comprises or consists of amino acids 161-285 of the DAF protein, wherein the amino acid positions are numbered corresponding to the amino acid positions set forth in SEQ ID NO: 1; and CCP15 of CR1 comprises or consists of amino acids 941-1001 of the CFH protein, or CCP8 comprises or consists of amino acids 491-551 of the CFH protein, wherein the amino acid positions are numbered corresponding to the amino acid positions set forth in SEQ ID NO: 3.
[0231] In some embodiments, CCP3-4 of DAF comprises or consists of amino acids 161-287 of the DAF protein, wherein the amino acid positions are numbered corresponding to the amino acid positions set forth in SEQ ID NO: 1; and CCP15 of CR1 comprises or consists of amino acids 941-1001 of the CFH protein, or CCP8 comprises or consists of amino acids 491-551 of the CFH protein, wherein the amino acid positions are numbered corresponding to the amino acid positions set forth in SEQ ID NO: 3.
[0232] In some specific embodiments, DAF is a human DAF protein, such as a human native DAF protein. In some specific embodiments, the DAF protein comprises
[0233] (i) the amino acid sequence shown in SEQ ID NO: 1,
[0234] (ii) the amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 2;
[0235] (iii) having at least 95%, 96%, 97%, 98%, or 99% amino acid sequence with the amino acid sequence shown in (i) or (ii);
[0236] Or it may consist of the amino acid sequence shown in any one of (i) to (iii).
[0237] In some specific embodiments, CFH is a human CFH protein, such as a native human CFH protein. In some specific embodiments, the CFH protein comprises
[0238] (i) the amino acid sequence shown in SEQ ID NO: 3 or 5,
[0239] (ii) the amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 4 or 6;
[0240] (iii) having at least 95%, 96%, 97%, 98%, or 99% amino acid sequence with the amino acid sequence shown in (i) or (ii);
[0241] Or it may consist of the amino acid sequence shown in any one of (i) to (iii).
[0242] In some specific embodiments, CR1 is a human CR1 protein, such as a native human CR1 protein. In some specific embodiments, the CR1 protein comprises
[0243] (i) the amino acid sequence shown in SEQ ID NO: 7,
[0244] (ii) the amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 8;
[0245] (iii) having at least 95%, 96%, 97%, 98%, or 99% amino acid sequence with the amino acid sequence shown in (i) or (ii);
[0246] Or it may consist of the amino acid sequence shown in any one of (i) to (iii).
[0247] In some embodiments, the hybrid protein of the present invention comprises the amino acid sequence of any one of SEQ ID NOs: 21-28, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence.
[0248] >Human CFHCCP1-2 or SCR1-2-Human DAF / CD55CCP4 or SCR4: (SEQ ID NO: 21)
[0249] >Human CFHCCP1-2 or SCR1-2-Human DAF / CD55CCP4 or SCR4: (SEQ ID NO: 22)
[0250] The CFH CCP1 / SCR1 region contains the point mutation V62I (in bold).
[0251] >Human CFHCCP1-2 or SCR1-2-Human DAF / CD55CCP4 or SCR4: (SEQ ID NO: 23)
[0252] The CFH CCP2 / SCR2 region contains three point mutations: E116T, Q119K, and V143E (in bold).
[0253] >Human CFHCCP1-2 or SCR1-2-Human DAF / CD55CCP4 or SCR4: (SEQ ID NO: 24)
[0254] The CFH CCP1 / SCR1 region contains the point mutation V62I (in bold).
[0255] The CFH CCP2 / SCR2 region contains three point mutations: E116T, Q119K, and V143E (in bold).
[0256] >Human CFHCCP1-2 or SCR1-2-Human DAF / CD55CCP4 or SCR4: (SEQ ID NO: 25)
[0257] Connected to the 6His tag, and DAF CCP4 extended two amino acid residues toward the C-terminus
[0258] >Human CFHCCP1-2 or SCR1-2-Human DAF / CD55CCP4 or SCR4: (SEQ ID NO: 26)
[0259] Connected to the 6His tag, and DAF CCP4 extended two amino acid residues toward the C-terminus
[0260] The CFH CCP1 / SCR1 region contains the point mutation V62I (in bold).
[0261] >Human CFHCCP1-2 or SCR1-2-Human DAF / CD55CCP4 or SCR4: (SEQ ID NO: 27)
[0262] Connected to the 6His tag, and DAF CCP4 extended two amino acid residues toward the C-terminus
[0263] The CFH CCP2 / SCR2 region contains three point mutations: E116T, Q119K, and V143E (in bold).
[0264] >Human CFHCCP1-2 or SCR1-2-Human DAF / CD55CCP4 or SCR4: (SEQ ID NO: 28)
[0265] Connected to the 6His tag, and DAF CCP4 extended two amino acid residues toward the C-terminus
[0266] The CFH CCP1 / SCR1 region contains the point mutation V62I (in bold).
[0267] The CFH CCP2 / SCR2 region contains three point mutations: E116T, Q119K, and V143E (in bold).
[0268] In some embodiments, the hybrid protein of the present invention comprises the amino acid sequence of SEQ ID NO: 29 or 30, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence.
[0269] >human CR1CCP15 or SCR15-human DAF / CD55CCP3-4 or SCR3-4): (SEQ ID NO: 29)
[0270] >human CR1CCP15 or SCR15-human DAF / CD55CCP3-4 or SCR3-4): (SEQ ID NO: 30)
[0271] Connected to the 6His tag, and DAF CCP4 extended two amino acid residues toward the C-terminus
[0272] III. Polynucleotides, Vectors, and Hosts
[0273] The present invention provides nucleic acids encoding any of the above hybrid proteins of the present invention. Also provided are vectors comprising the nucleic acids. In one embodiment, the vector is an expression vector (e.g., a pCDNA vector, e.g., pCDNA3.1). Also provided are host cells comprising the nucleic acids or the vectors. In one embodiment, the host cell is eukaryotic. In another embodiment, the host cell is selected from yeast cells or mammalian cells (e.g., CHO cells or 293 cells, e.g., Expi293 cells). In another embodiment, the host cell is prokaryotic.
[0274] In one aspect, the present invention provides nucleic acids encoding any of the above hybrid proteins. When expressed from a suitable expression vector, the polypeptide encoded by the nucleic acid can exhibit the functions of DAF and / or CFH, such as dissociating C3 and / or C5 convertases, accelerating decay activity against the classical pathway C3 convertase and / or the alternative pathway C3 convertase, dissociating the alternative pathway C3 convertase C3bBb, or binding to C3b, and having biased complement inhibition activity, including inhibition of the alternative pathway (AP) without substantially inhibiting the classical pathway (CP).
[0275] To facilitate production and purification, the hybrid protein can be fused to a secretory signal peptide at the N-terminus, and / or a tag peptide that facilitates purification, such as a hexahistidine tag or a biotin tag.
[0276] As will be apparent to those skilled in the art, due to codon degeneracy, each hybrid protein can be encoded by multiple nucleic acid sequences.
[0277] In some embodiments, the nucleic acid of the invention comprises a nucleic acid encoding an amino acid sequence selected from any one of SEQ ID NOs: 21-30, or a nucleic acid encoding an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to an amino acid sequence selected from any one of SEQ ID NOs: 21-30.
[0278] Nucleic acid sequences encoding molecules of the present invention can be generated using methods well known in the art, such as de novo solid phase DNA synthesis or PCR amplification.
[0279] In one embodiment, one or more vectors comprising nucleic acid of the present invention are provided. In one embodiment, the vector is an expression vector, such as a prokaryotic expression vector or a eukaryotic expression vector. Vectors include but are not limited to viruses, plasmids, cosmids, lambda phages, or yeast artificial chromosomes (YACs). In a preferred embodiment, the expression vector is pCDNA, such as pCDNA3.1.
[0280] In one embodiment, a host cell comprising one or more polynucleotides of the present invention is provided. In some embodiments, a host cell comprising an expression vector of the present invention is provided. As used herein, the term "host cell" refers to any type of cell system that can be engineered to produce a protein of the present invention. Host cells suitable for replication and support expression of proteins of the present invention are well known in the art. As needed, such cells can be transfected or transduced with specific expression vectors, and a large number of cells containing the vector can be cultivated for inoculating large-scale fermenters to obtain sufficient amounts of the protein of the present invention for clinical applications.
[0281] Suitable host cells include prokaryotic microorganisms such as Escherichia coli, eukaryotic microorganisms such as filamentous fungi or yeast, or various eukaryotic cells such as Chinese hamster ovary cells (CHO), insect cells, etc. Mammalian cell lines suitable for suspension culture can be used. Examples of useful mammalian host cell lines include SV40-transformed monkey kidney CV1 line (COS-7); human embryonic kidney line (HEK 293 or 293F cells or 293FT cells), baby hamster kidney cells (BHK), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical cancer cells (HELA), canine kidney cells (MDCK), Buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (Hep G2), CHO cells, NSO cells, myeloma cell lines such as YO, NSO, P3X63 and Sp2 / 0, etc. Mammalian host cell lines suitable for producing proteins are known in the art. In a preferred embodiment, the host cell is CHO or HEK293 cells or Expi293 cells.
[0282] IV. Production and Purification of the Molecules of the Invention
[0283] In another aspect, the present invention provides a method for producing a hybrid protein of the present invention, the method comprising: culturing a host cell comprising a nucleic acid molecule encoding the protein under conditions suitable for expressing the hybrid protein, optionally further comprising isolating the protein from the host cell or the host cell culture medium, and / or purifying the protein.
[0284] For recombinant production, the polynucleotide encoding the protein of the present invention can be inserted into a vector for further cloning and / or expression in a host cell. Methods well known to those skilled in the art can be used to construct expression vectors. Once an expression vector comprising the polynucleotide of the present invention has been prepared for expression, the expression vector can be transfected or introduced into a suitable host cell. A variety of techniques can be used to achieve this purpose, for example, protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, gene gun, liposome-based transfection or other conventional techniques.
[0285] Proteins prepared as described herein can be purified by known techniques such as nickel columns, high performance liquid chromatography, affinity chromatography, ion exchange chromatography, gel electrophoresis, etc. The actual conditions used to purify a particular protein will also depend on factors such as net charge, hydrophobicity, hydrophilicity, etc., and these will be apparent to those skilled in the art.
[0286] The purity and quantity of the proteins of the invention can be determined by any of a variety of well-known analytical methods.
[0287] V. Assay
[0288] The hybrid proteins provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activities by a variety of assays known in the art.
[0289] The hemolysis inhibitory effect of the hybrid protein of the present invention can be measured by methods known in the art, such as in vitro assays and / or in vivo animal experiments. For example, a hemolysis assay, such as the methods described in Examples 4.1 and 4.2, can be used to detect the hemolysis inhibitory effect of the molecule on the classical complement immunity pathway and / or the alternative complement immunity pathway.
[0290] VI. Pharmaceutical Compositions, Drug Combinations, and Kits
[0291] In one aspect, the present invention provides a composition, eg, a pharmaceutical composition, medicament or formulation, comprising a hybrid protein of the present invention or a nucleic acid molecule encoding the same.
[0292] In one embodiment, the composition further comprises pharmaceutical excipients, such as pharmaceutical carriers, pharmaceutical excipients, including buffers, known in the art.
[0293] As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, isotonic and absorption delaying agents that are physiologically compatible. For the use of pharmaceutical excipients and their applications, see also "Handbook of Pharmaceutical Excipients", 8th edition, RC Rowe, PJ Eskey and S C Owen, Pharmaceutical Press, London, Chicago.
[0294] The compositions or medicines or preparations of the present invention can be in various forms. These forms include, for example, liquid, semisolid and solid dosage forms, such as liquid solutions (e.g., injections), powders or suspensions, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic use.
[0295] The compositions, medicaments or formulations of the invention may also comprise, in addition to the hybrid proteins of the invention or nucleic acids encoding the same, other therapeutic agents, which are required for the specific indication being treated and which preferably do not adversely affect the activity of each other. Thus, in one embodiment, the composition, formulation or medicament, e.g., a pharmaceutical composition, comprises a combination of one or more molecules of the invention and one or more other therapeutic agents.
[0296] The composition of the present invention or medicine or preparation can be in various forms. These forms include, for example, liquid, semisolid and solid dosage forms, such as liquid solutions (e.g., injections), powders or suspensions, liposomes and suppositories. The composition of the present invention or medicine or preparation is suitable for intravenous injection, intravenous infusion, intraperitoneal, intradermal, intramuscular, subcutaneous and intranasal administration (e.g., by injection or infusion). The preferred form depends on the intended mode of administration and therapeutic use.
[0297] The present invention also provides a pharmaceutical combination or pharmaceutical combination product comprising the hybrid protein of the present invention or a nucleic acid encoding the same and one or more other therapeutic agents.
[0298] The present invention also provides a complete kit comprising the drug combination, for example, the complete kit comprises in the same package:
[0299] - a first container containing a pharmaceutical composition comprising the hybrid protein of the present invention or a nucleic acid encoding the same;
[0300] - Optionally, a second container further comprising a pharmaceutical composition comprising one or more additional therapeutic agents (in some embodiments, the two or more additional therapeutic agents are in the same container, or in separate containers).
[0301] VII. Uses and Methods
[0302] In one aspect, the present invention provides a method for preventing or treating a disease or disorder associated with the complement system in a subject, comprising administering to the subject an effective amount of the hybrid protein of the present invention or a nucleic acid encoding the same, or a composition, drug or formulation comprising the same.
[0303] In some embodiments, the complement system-related disease is caused by abnormal activation of the complement system or dysregulation of the complement system, in particular abnormal activation or dysregulation of the alternative complement pathway. In some embodiments, abnormal activation of the complement system or dysregulation of the complement system, in particular abnormal activation or dysregulation of the alternative complement pathway, is due to, for example, microbial infection or an increase in autoimmune antibodies, or due to a decrease, loss, disability or functional interference or blockage of complement regulatory proteins.
[0304] In some embodiments, the treatment of the disease would benefit from inhibition of the activity of the complement system, particularly biased inhibition of the alternative complement pathway.
[0305] In other aspects, the present invention provides the use of a molecule of the invention or a composition comprising the same in the production or preparation of a medicament for the uses described herein, e.g., for preventing or treating a disease or disorder associated with the complement system mentioned herein, e.g., a disease or disorder associated with abnormal activation or dysregulation of the alternative complement pathway.
[0306] In some embodiments, the complement system-related disease or disorder may be a disease requiring hemolysis inhibition, such as a disease requiring inhibition of hemolysis of the classical complement immune pathway and / or the alternative complement immune pathway.
[0307] In some embodiments, the disease or disorder associated with the complement system is a disease in which inhibition of the activity of the alternative complement pathway is desired, such as dense deposit disease (DDD), age-related macular degeneration (AMD), membranoproliferative glomerulonephritis type II (MPGNII), hemolytic uremic syndrome (HUS), asthma, amyloidosis, glomerulonephritis (e.g., immune complex glomerulonephritis), membranous nephritis, transplant rejection, antiphospholipid antibody syndrome, pemphigus, intestinal inflammation, lupus nephritis, disease associated with eye drops, or thrombotic thrombocytopenic purpura.
[0308] In some preferred embodiments, the complement system-associated disease or disorder is a disease that requires inhibition of the activity of the alternative complement pathway but retention of the activity of the classical complement pathway, such as dense deposit disease (DDD), age-related macular degeneration (AMD), membranoproliferative glomerulonephritis type II (MPGNII), hemolytic uremic syndrome (HUS), asthma, amyloidosis, glomerulonephritis (e.g., immune complex glomerulonephritis), membranous nephritis, transplant rejection, antiphospholipid antibody syndrome, pemphigus, intestinal inflammation, lupus nephritis, diseases associated with eye drops, or thrombotic thrombocytopenic purpura.
[0309] In some embodiments, the hybrid protein of the present invention, or the nucleic acid encoding the same, or the composition, medicament, or formulation comprising the protein or nucleic acid, delays the onset of a disorder and / or symptoms associated with the disorder.
[0310] In some embodiments, the hybrid protein of the present invention or the nucleic acid encoding the same or the composition or drug or formulation comprising the protein or nucleic acid can also be administered in combination with one or more other therapies, such as treatment modalities and / or other therapeutic agents, for the purposes described herein, for example, for preventing and / or treating the relevant diseases or conditions mentioned herein.
[0311] The administration route of the hybrid protein of the present invention, or the nucleic acid encoding the same, or the composition, drug, or formulation comprising the protein or nucleic acid is according to known methods, for example, injection or infusion.
[0312] The present invention further encompasses the use of the hybrid protein of the present invention or the nucleic acid encoding the same, or a composition or formulation comprising the protein or nucleic acid, in the preparation of a medicament for the uses described herein, e.g., for preventing and / or treating the relevant diseases or conditions mentioned herein. Example
[0313] Example 1. Molecular Construction
[0314] To construct protein expression vectors for the hybrid molecules and complement regulatory molecules described in the present invention, conventional molecular cloning techniques were used, using synthetic gene DNA (Suzhou Jinweizhi Biotechnology / Shanghai Sangon Biosynthesis) as a template. The DNA encoding each protein was subcloned into the pCDNA3.1 expression vector (purchased from Biowind). After plasmid sequencing verification, the protein was used for transient expression. Each encoded protein had a signal peptide (MGWSCIILFLVATATGVHS) added to the N-terminus and a 6xHis tag (GHHHHHH) added to the C-terminus to facilitate subsequent secretory expression in mammalian cells and nickel column purification.
[0315] The amino acid sequences of the encoded proteins are as follows:
[0316] >CR13m (human CR1CCP1-3 or SCR1-3, containing N29K, S37Y, G79D and D109N mutations (in bold), sequence derived from patent US9988611_B2): SEQ ID NO: 35
[0317] >D24 (human DAF / CD55CCP2-4 or SCR2-4, sequence reference Hui-fen Zhang et al. THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 276, No. 29, Issue of July 20, pp. 27290-27295, 2001): SEQ ID NO: 36
[0318] >F15 (human CFH CCP1-5 or SCR1-5, containing the V62I mutation (in bold), sequence reference Masha Fridkis-Hareli et al. Blood. 2011 Oct 27; 118(17): 4705-4713 and Agustín Tortajada et al. Hum Mol Genet. 2009 September 15; 18(18): 3452-3461): SEQ ID NO: 37
[0319] >F12D4 (a hybrid molecule of the invention, comprising human CFH CCP1-2 or SCR1-2 and human DAF / CD55CCP4 or SCR4, wherein the CFH CCP2 / SCR2 region comprises three point mutations (in bold), wherein the mutated amino acids are derived from the corresponding amino acids of DAF CCP3 / SCR3): SEQ ID NO: 38, wherein the sequence of the signal peptide attached to the N-terminus is SEQ ID NO: 38
[0320] >CR15D34 (hybrid molecule of the present invention, human CR1CCP15 or SCR15-human DAF / CD55CCP3-4 or SCR3-4): SEQ ID NO: 39
[0321] >FH13 (human CFH CCP1-3 or SCR1-3): SEQ ID NO: 40
[0322] >D14 (human DAF / CD55CFH CCP1-4 or SCR1-4): SEQ ID NO: 41
[0323] Example 2. Protein expression
[0324] After plasmid was amplified by DH5α strain (Yisheng Bio), the plasmid was prepared using NucleoBond Xtra Midi Plus (MACHEREY-NAGEL, see product manual for details). The prepared plasmid was transfected into Expi293 cells (purchased from Thermo Fisher) using PEI (PolyScience) for transient protein expression (refer to V., et al. BMC Biotechnol 13, 52, 2013.). The harvested supernatant was affinity purified using a nickel ion prepacked column (GE Life Sciences, HisTrap HP, see product manual for details), dialyzed against PBS, and the exchanged solution was sterilized by filtration through a 0.2 μm filter. Protein quantification was performed using the NanoDrop (Thermofisher) A280 method based on the theoretical extinction coefficient.
[0325] Example 3. Protein purity detection
[0326] SDS-PAGE
[0327] 2.5 μg of protein was added to the sample buffer containing reducing agent and the sample buffer without reducing agent (Sangon Biotechnology) in proportion. The sample containing reducing agent was boiled at 95℃ for 5 minutes to fully denature the protein. The sample without reducing agent was added to the sample without heat treatment. 10% Precast-GLgel Tris-Glycine electrophoresis precast gel (Sangon Biotechnology) was used. Electrophoresis was performed using a Tetra electrophoresis system (BioRad). After electrophoresis, the gel was stained with 0.1% Coomassie Brilliant Blue and decolorized with an ethanol-glacial acetic acid solution. SDS-PAGE electrophoresis results showed that, with the exception of a slightly diffuse D14 protein band, the remaining protein bands were relatively clear, indicating that the purity of each protein was high under both reducing and non-reducing conditions (as shown in Figure 2). Furthermore, due to differences in protein reduction, denaturation, and modification states, as well as electrophoresis conditions, the electrophoretic molecular weight may differ from the theoretical molecular weight.
[0328] HPLC-SEC
[0329] Approximately 50 μg of purified protein sample was applied to a 300×4.6 mm, 5 μm column (TOSOH) of TSKgelSuper SW3000. SEC detection was performed using a U3000 HPLC instrument (DIONEX). All proteins were detected using UV at 280 nm and 214 nm. Elution was performed by isocratic elution at a flow rate of 0.25 mL / min. The analytical results showed that the purity of the hybrid protein F12D4 purified in one step using a nickel column was excellent, with a monomer purity of more than 98%. The purity of the hybrid protein CR15D34 was good, with a monomer purity of more than 70%, but with a large number of protein aggregates (as shown in Figures 3 and 4).
[0330] Example 4. Complement Inhibitory Activity Detection
[0331] 4.1 Complement Classical Pathway (CP) Inhibitory Activity Assay
[0332] This experiment analyzed and compared the inhibitory activity of each protein on complement CP by detecting the degree of inhibition of different concentrations of the test protein on hemolysin-mediated sheep erythrocyte hemolysis caused by normal human serum complement activity.
[0333] The experimental process is briefly described as follows:
[0334] (1) Protein gradient dilution: The protein was prepared into a 12000 nM solution using GVB++ buffer (gelatin-Flona buffer containing Ca2+ and Mg2+, product number: 25-02080, Tian Enze), and then diluted 4-fold in a gradient, for a total of 7 gradients;
[0335] (2) Serum dilution: Normal human serum NHS (Shanghai Rubai Biotechnology) was taken out from a -70°C freezer, thawed naturally at 4°C, and diluted to 4% with GVB++ buffer;
[0336] (3) Activation of sheep erythrocytes: Sheep erythrocytes (Nanjing Senbega Biotechnology) were washed with GVB++ buffer until the supernatant was transparent, and then resuspended with GVB++ buffer. Hemolysin (BM351Y, Beijing Borsi) was added to the erythrocyte suspension at a dilution of 1:4000, and incubated at 4°C for 15 minutes to activate the sheep erythrocytes. The activated sheep erythrocytes were washed twice with GVB++ and resuspended in GVB++ buffer.
[0337] (4) Incubation: 25 μL of the diluted protein and serum were mixed in a 96-well plate, and then 50 μL of the red blood cell suspension obtained in step (3) was added to make the initial protein concentration 3000 nM and the final serum concentration 1%. After thorough mixing, the plate was placed in a 37°C constant temperature incubator for 1 hour, and a negative control (containing only serum) and a positive control (containing only serum and red blood cells) were set up;
[0338] (5) Termination: After the incubation, add 100 μL of 20 mM EDTA-GVB buffer (GVBE) to each reaction well to terminate the reaction;
[0339] (6) Reading: Centrifuge the 96-well plate at 3000 rpm for 5 minutes, transfer 100 μL of the supernatant to a new 96-well flat-bottom plate, measure the absorbance at OD405 nm in a multifunctional plate reader, and save the data;
[0340] (7) Data processing: The obtained OD405nm reading was substituted into the following formula to calculate the erythrocyte hemolysis inhibition rate:
[0341] Hemolysis inhibition rate (%) = (positive control reading - experimental group reading) / (positive control reading - negative control reading) * 100%
[0342] Then, a four-parameter fitting plot was performed with the final protein concentration as the abscissa and the hemolysis inhibition rate as the ordinate to calculate the IC50 value of the measured inhibitory protein.
[0343] The results of the CP hemolytic inhibition assay showed that the CFH and DAF hybrid protein F12D4 exhibited weak CP inhibitory activity, significantly weaker than the CR1 activity-enhancing fragment CR13m and DAF fragment D24, and significantly weaker than the CFH fragment FH15 and DAF fragment D14. The CR1 and DAF hybrid protein CR15D34 exhibited only weak CP inhibitory activity, while the CFH fragment FH13 exhibited virtually no CP inhibitory activity (as shown in Figure 5). This indicates that both hybrid proteins obtained through domain hybridization exhibited weak CP inhibitory activity.
[0344] 4.2 Complement alternative pathway (AP) inhibitory activity assay
[0345] This experiment analyzed and compared the inhibitory activity of each protein on complement AP by measuring the degree of inhibition of different concentrations of the test protein on rabbit erythrocyte hemolysis caused by normal human serum complement activity.
[0346] The experimental process is briefly described as follows:
[0347] (1) Protein gradient dilution: The protein was prepared into a 28000 nM solution using GVBMG buffer (Gelatin-Flona buffer containing Mg2+ and EGTA, product number: 25-02090, Tian Enze), and then diluted 4-fold in a gradient, for a total of 7 gradients;
[0348] (2) Serum dilution: Normal human serum NHS (Shanghai Rubai Biotechnology) was taken out from a -70°C freezer, thawed naturally at 4°C, and diluted to 60% with GVBMG;
[0349] (3) Preparation of rabbit erythrocytes: Rabbit erythrocytes (Nanjing Senbega Biotechnology) were washed with GVBMG until the supernatant was transparent, and then the erythrocytes were resuspended in GVBMG;
[0350] (4) Incubation: 25 μL of the diluted protein and serum were mixed in a 96-well plate, and then 50 μL of the red blood cell suspension from step (3) was added to make the initial protein concentration 7000 nM and the final serum concentration 15%. After thorough mixing, the plate was placed in a 37°C constant temperature incubator for 1 hour. A negative control (containing only serum) and a positive control (containing only serum and red blood cells) were set up;
[0351] (5) Termination: After the incubation, add 100 μL of 10 mM EDTA-GVB buffer (GVBE) to each reaction well to terminate the reaction;
[0352] (6) Reading: Centrifuge the 96-well plate at 3000 rpm for 5 minutes, transfer 100 μL of the supernatant to a new 96-well flat-bottom plate, measure the absorbance at OD405 nm in a multifunctional plate reader, and save the data;
[0353] (7) Data processing: The obtained OD405nm reading was substituted into the following formula to calculate the erythrocyte hemolysis inhibition rate:
[0354] Hemolysis inhibition rate (%) = (positive control reading - experimental group reading) / (positive control reading - negative control reading) * 100%
[0355] Then, a four-parameter fitting plot was performed with the final protein concentration as the horizontal axis and the hemolysis inhibition rate as the vertical axis to calculate the IC50 value of the measured inhibitory protein. The results are shown in Figure 6.
[0356] The results of the AP hemolytic inhibition assay showed that the CFH and DAF hybrid protein F12D4 exhibited potent AP inhibitory activity, significantly superior to the CFH fragment FH15 and the CR1 activity-enhancing fragment CR13m, as well as DAF fragments D24 and D14 and CFH fragment FH13, which had only weak AP inhibitory activity. Another CR1 and DAF hybrid protein, CR15D34, also exhibited good AP inhibitory activity, surpassing DAF fragments D24 and D14 and CFH fragment FH13, and showing activity roughly comparable to that of the CFH fragment FH15 and the CR1 activity-enhancing fragment CR13m (as shown in Figure 6). This indicates that both hybrid proteins obtained through domain hybridization possess biased AP inhibitory activity, with F12D4 exhibiting stronger AP inhibitory activity.
[0357] Sequence Listing
Claims
1. A hybrid protein comprising (i) CCP1-2 of human complement factor H (CFH), (ii) CCP4 of human decay accelerating factor (DAF), and optionally a signal peptide and / or a tag; Or composed of the above.
2. The hybrid protein of claim 1, wherein CCP1 and CCP2 of CFH are directly linked together to form CCP1-2.
3. The hybrid protein of claim 1 or 2, wherein CCP1 of human CFH comprises or consists of the amino acid sequence at positions 19 to 82 of the human CFH protein; and / or CCP2 of human CFH comprises or consists of the amino acid sequence at positions 83 to 143 of the human CFH protein, Optionally, the CCP1 comprises a V62I mutation, Optionally, the CCP2 comprises one, two or three of E116T, Q119K and V143E mutations, The amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO:
3.
4. The hybrid protein of claim 1 or 2, wherein CCP1-2 of human CFH comprises or consists of the amino acid sequence of positions 19-143 of human CFH protein, Optionally, the CCP1-2 comprises one, two, three or four of the mutations V62I, E116T, Q119K and V143E, The amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO:
3.
5. The hybrid protein according to any one of claims 1 to 4, wherein CCP4 of human DAF comprises or consists of the amino acid sequence of amino acids 223 to 285 of human DAF protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO:
1.
6. The hybrid protein according to any one of claims 1 to 4, wherein CCP4 of human DAF comprises or consists of the amino acid sequence of amino acids 223 to 287 of human DAF protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO:
1.
7. The hybrid protein of claim 2, wherein (1) CCP1 of human CFH comprises or consists of the amino acid sequence of positions 19 to 82 of human CFH protein, CCP2 of CFH comprises or consists of the amino acid sequence of positions 83-143 of human CFH protein, and CCP4 of human DAF comprises or consists of the amino acid sequence 223-285 of the human DAF protein; (2) CCP1 of human CFH comprises or consists of the amino acid sequence of positions 19 to 82 of the human CFH protein, CCP2 of human CFH comprises or consists of the amino acid sequence of positions 83 to 143 of the human CFH protein, and CCP4 of human DAF comprises or consists of the amino acid sequence of positions 223 to 287 of the human DAF protein; (3) CCP1-2 of human CFH comprises or consists of the amino acid sequence of positions 19 to 143 of the human CFH protein, and CCP4 of human DAF comprises or consists of the amino acid sequence of positions 223 to 285 of the human DAF protein; or (4) CCP1-2 of human CFH comprises or consists of the amino acid sequence of positions 19 to 143 of the human CFH protein, and CCP4 of human DAF comprises or consists of the amino acid sequence of positions 223 to 287 of the human DAF protein; The amino acid positions of the human CFH protein correspond to the amino acid position numbers shown in SEQ ID NO:3, and the amino acid positions of the human DAF protein correspond to the amino acid position numbers shown in SEQ ID NO:
1.
8. The hybrid protein of claim 7, wherein CCP1 of human CFH comprises a V62I mutation, CCP2 of human CFH comprises one, two or three of E116T, Q119K and V143E mutations, and / or CCP1-2 of human CFH comprises one, two, three or four of V62I mutation, E116T, Q119K and V143E mutations.
9. The hybrid protein according to any one of claims 1 to 8, wherein the human CFH protein is a human native CFH protein or a protein comprising (i) the amino acid sequence shown in SEQ ID NO: 3 or 5, (ii) the amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 4 or 6; (iii) having at least 95%, 96%, 97%, 98%, or 99% amino acid sequence with the amino acid sequence shown in (i) or (ii); Or it may consist of the amino acid sequence shown in any one of (i) to (iii).
10. The hybrid protein according to any one of claims 1 to 9, wherein the human DAF protein is human native DAF protein or a protein comprising (i) the amino acid sequence shown in SEQ ID NO: 1, (ii) the amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 2; (iii) having at least 95%, 96%, 97%, 98%, or 99% amino acid sequence with the amino acid sequence shown in (i) or (ii); Or it may consist of the amino acid sequence shown in any one of (i) to (iii).
11. The hybrid protein according to any one of claims 1 to 10, wherein The CCP1 of human CFH comprises the amino acid sequence of SEQ ID NO: 14 or 15, or comprises an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% identity with the amino acid sequence of SEQ ID NO: 14 or 15, or consists of said sequence; The CCP2 of human CFH comprises the amino acid sequence of SEQ ID NO: 16 or 17, or comprises an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% identity with the amino acid sequence of SEQ ID NO: 16 or 17, or consists of said sequence; The CCP1-2 of human CFH comprises the amino acid sequence of SEQ ID NO: 31, 32, 33 or 34, or comprises an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% identity with the amino acid sequence of SEQ ID NO: 31, 32, 33 or 34, or consists of the sequence; and / or The CCP4 of human DAF comprises the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11, or comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11, or consists of the sequence.
12. The hybrid protein according to any one of claims 1 to 11, wherein the tag is, for example, a purification tag, such as a hexahistidine tag or a biotin tag, for example, comprising the amino acid sequence shown in SEQ ID NO:
19.
13. The hybrid protein according to any one of claims 1 to 12, wherein the signal peptide is a secretory signal peptide, for example, it comprises the amino acid sequence shown in SEQ ID NO:
20.
14. The hybrid protein of any one of claims 1-13, wherein the hybrid protein comprises the amino acid sequence of any one of SEQ ID NOs: 21-28, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence.
15. A hybrid protein comprising (i) CCP15 or CCP8 of human complement receptor 1 (CR1), (ii) CCP3-4 of human decay accelerating factor (DAF), and optionally a signal peptide and / or a tag; Or composed of the above.
16. The hybrid protein of claim 15, wherein CCP3 and CCP4 of DAF are directly linked together to form CCP3-4.
17. The hybrid protein of claim 15 or 16, wherein CCP15 of human CR1 comprises the amino acid sequence of positions 941-1001 of human CFH protein, or CCP8 comprises the amino acid sequence of positions 491-551 of human CR1 protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO:
3.
18. The hybrid protein according to any one of claims 15 to 17, wherein CCP3 of human DAF comprises or consists of the amino acid sequence of amino acids 161 to 222 of human DAF protein, and / or CCP4 of human DAF comprises or consists of the amino acid sequence of amino acids 223 to 285 of human DAF protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO:
1.
19. The hybrid protein according to any one of claims 15 to 17, wherein CCP3 of human DAF comprises or consists of the amino acid sequence of amino acids 161 to 222 of human DAF protein, and / or CCP4 of human DAF comprises or consists of the amino acid sequence of amino acids 223 to 287 of human DAF protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO:
1.
20. The hybrid protein of claim 16 or 17, wherein CCP3-4 of human DAF comprises or consists of the amino acid sequence of positions 161-285 of the human DAF protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO:
1.
21. The hybrid protein of claim 16 or 17, wherein CCP3-4 of human DAF comprises or consists of the amino acid sequence of positions 161-287 of the human DAF protein, wherein the amino acid positions correspond to the amino acid position numbers shown in SEQ ID NO:
1.
22. The hybrid protein of claim 16, wherein (1) CCP15 of human CR1 comprises or consists of the amino acid sequence of positions 941 to 1001 of human CR1 protein, and CCP3 of human DAF comprises or consists of the amino acid sequence of positions 161 to 222 of human DAF protein, and CCP4 of human DAF comprises or consists of the amino acid sequence of amino acids 223 to 285 of the human DAF protein; or (2) CCP15 of human CR1 comprises or consists of the amino acid sequence of positions 941 to 1001 of the human CR1 protein, and CCP3 of human DAF comprises or consists of the amino acid sequence of positions 161 to 222 of the human DAF protein, and CCP4 of human DAF comprises or consists of the amino acid sequence of amino acids 223-287 of human DAF protein; or (3) CCP15 of human CR1 comprises or consists of the amino acid sequence at positions 941-1001 of the human CR1 protein, and CCP3-4 of human DAF comprises or consists of the amino acid sequence at positions 161-285 of the human DAF protein; (4) CCP15 of human CR1 comprises or consists of the amino acid sequence at positions 941-1001 of the human CR1 protein, and CCP3-4 of human DAF comprises or consists of the amino acid sequence at positions 161-287 of the human DAF protein; The amino acid positions of the human CR1 protein correspond to the amino acid position numbers shown in SEQ ID NO:7, and the amino acid positions of the human DAF protein correspond to the amino acid position numbers shown in SEQ ID NO:
1.
23. The hybrid protein according to any one of claims 16 to 22, wherein the human CR1 protein is a human native CR1 protein or a protein comprising (i) the amino acid sequence shown in SEQ ID NO:7, (ii) the amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 8; (iii) having at least 95%, 96%, 97%, 98%, or 99% amino acid sequence with the amino acid sequence shown in (i) or (ii); Or it may consist of the amino acid sequence shown in any one of (i) to (iii).
24. The hybrid protein according to any one of claims 15 to 23, wherein the human DAF protein is a human native DAF protein or a protein comprising (i) the amino acid sequence shown in SEQ ID NO: 1, (ii) the amino acid sequence encoded by the nucleic acid sequence shown in SEQ ID NO: 2; (iii) having at least 95%, 96%, 97%, 98%, or 99% amino acid sequence with the amino acid sequence shown in (i) or (ii); Or it may consist of the amino acid sequence shown in any one of (i) to (iii).
25. The hybrid protein according to any one of claims 18 to 24, wherein The CCP15 or CCP8 of the human CR1 comprises the amino acid sequence of SEQ ID NO: 18, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 18; The CCP3 of human DAF comprises the amino acid sequence of SEQ ID NO: 9, or comprises an amino acid sequence having at least 95%, 96%, 97%, 98% or 99% identity with the amino acid sequence of SEQ ID NO: 9, or consists of said sequence; The CCP4 of human DAF comprises the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11, or comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 10 or SEQ ID NO: 11, or consists of said sequence; The CCP3-4 of human DAF comprises the amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 13, or comprises an amino acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of SEQ ID NO: 12 or SEQ ID NO: 13, or consists of the sequence.
26. The hybrid protein according to any one of claims 16 to 25, wherein the tag is, for example, a purification tag, such as a hexahistidine tag or a biotin tag, for example, comprising the amino acid sequence shown in SEQ ID NO:
19.
27. The hybrid protein according to any one of claims 16 to 26, wherein the signal peptide is a secretory signal peptide, for example, it comprises the amino acid sequence shown in SEQ ID NO:
20.
28. The hybrid protein of any one of claims 16-27, wherein the hybrid protein comprises the amino acid sequence of SEQ ID NO: 29 or 30, or comprises or consists of an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99% identical to the amino acid sequence.
29. A nucleic acid molecule encoding the hybrid protein of any one of claims 1-28.
30. An expression vector comprising the nucleic acid molecule of claim 29, preferably, the expression vector is pCDNA3.
1.
31. A host cell comprising the nucleic acid molecule of claim 29 or the expression vector of claim 30, preferably, the host cell is prokaryotic or eukaryotic, such as 293 cells, such as Expi293 cells.
32. A method for preparing a hybrid protein as described in any one of claims 1-28, comprising culturing a host cell according to claim 31 under conditions suitable for expression of the hybrid protein, and optionally further comprising isolating the protein from the host cell or the host cell culture medium, and / or purifying the protein.
33. A pharmaceutical composition or drug or formulation comprising the hybrid protein or nucleic acid molecule encoding the hybrid protein according to any one of claims 1 to 28, or the nucleic acid molecule according to claim 29, and optionally a pharmaceutically acceptable excipient.
34. A drug combination product comprising The hybrid protein or the nucleic acid molecule encoding the same according to any one of claims 1 to 28, or the nucleic acid molecule according to claim 29; and Other Therapeutic Agents.
35. A method for preventing or treating a disease or condition associated with the complement system in a subject, comprising administering to the subject an effective amount of a hybrid protein according to any one of claims 1 to 28 or a nucleic acid molecule encoding the same; or a nucleic acid molecule according to claim 29; or a pharmaceutical composition or formulation according to claim 33; or a pharmaceutical combination product according to claim 34.
36. The method of claim 35, wherein the disease or disorder is due to abnormal activation of the complement system or dysregulation of the complement system.
37. The method of claim 36, wherein the abnormal activation of the complement system or the dysregulation of the complement system is due to, for example, microbial infection or an increase in autoimmune antibodies, or due to a decrease, deletion, inability or functional disruption, blockage of complement regulatory proteins.
38. The method of claim 37, wherein the complement system-related disease or disorder is selected from diseases resulting from activation of the alternative pathway, such as diseases requiring inhibition of the alternative pathway of complement immunity and optionally without inhibition of the classical pathway of complement immunity, such as paroxysmal nocturnal hemoglobinuria.
Citation Information
Patent Citations
Protein inhibitors to complement and VEGF pathways and methods of use thereof
US9988611B2
Recombinant complement factor H-immunoglobulin fusion protein with complement regulating activity and preparation method and application thereof
CN106928371A
Complement inhibitors and uses thereof
CN109689084A
Complement inhibitors and uses thereof
CN113365648A
Hybrid and chimeric polypeptides that regulate activation of complement
WO2005069726A2
